Unlocking the Immune System (with Luis Voloch from Immunai)

06 Apr 2022

Current cancer therapies are difficult, expensive and slow to develop. But the combination of new computers and new biological technologies leads to a better understanding of the human immune system, with the aim of offering a better class of cancer therapies.

Azeem Azhar speaks with Luis Voloch, co-founder and chief technology officer of Immunai, about how AI is unlocking the secrets of the immune system and opening new avenues for new cancer treatments.

They also discuss:

Why Luis and his co-founder, two machine learning engineers, decided to start a bio-startup. How Immunai uses single-cell genomics to map the immune system. The trajectory of Immunai’s experiments from the laboratory to the patient.


Further sources:
Scaling Synthetic Biology (with Gingko’s Reshma Shetty), Exponential View Podcast, 2022
The Future of Healthcare: Personalization and AI (with ZOE’s Jonathan Wolf), Exponential View Podcast, 2022

A transcript of this episode will be available by April 13, 2022.

This post Unlocking the Immune System (with Luis Voloch from Immunai) was original published at “https://hbr.org/podcast/2022/04/ai-and-cancer-unlocking-the-immune-system-with-immunais-luis-voloch”


Please enter your comment!
Please enter your name here